Abstract:CD147/extracellular matrix metalloproteinase inducer (EMMPRIN) expressed by tumor cells stimulates peri-tumorous fibroblasts to produce matrix metalloproteinases (MMPs), thus contributing to tumor invasion and metastasis. To assess its suitability as a potential therapeutic target, as well as its association with the clinicopathologic features and the prognosis of patients, the expression of CD147/EMMPRIN in neoplastic tissues of the genitourinary system were analyzed.CD147/EMMPRIN expression in 52 patients with renal carcinoma, 58 patients with bladder carcinoma, 101 patients with prostate carcinoma, 17 patients of penis carcinoma, and 17 patients of testis carcinoma were examined by immunostaining on paraffin-embedded tumor specimens using monoclonal antibodies. Then, the association of its expression with clinicopathologic characteristics to the patients' prognosis was analyzed. The RNA interference approach was used to silence CD147/EMMPRIN expression in the human prostate carcinoma cell line LNCAP and human bladder carcinoma cell line J82. The in vitro proliferative ability of CD147/EMMPRIN-deficient cells was determined by a 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide MTT assay.CD147/EMMPRIN was expressed in neoplastic tissues, but not in normal tissues. Positive expression was shown in 42 of 52 (80.77%) of the patients with renal carcinoma, 41 of 58 (70.69%) of the patients with bladder carcinoma, 67 of 101 (66.34%) of the patients with prostate carcinoma, 16 of 17 (94.12%) of the patients with penis carcinoma and testis carcinoma. Positive CD147/EMMPRIN staining was significantly associated with TNM stages and histological subtypes of patients with various urinary carcinomas (P < 0.05). In all five groups, for different expression levels of CD147/EMMPRIN, the patients with a highly positive expression of CD147/EMMPRIN had the poorest prognosis. The siRNA-treated cells exhibited significantly decreased growth ability compared with control cells in vitro.These results may assist in defining the suitability of CD147/EMMPRIN as a therapeutic target and as a method for predicting a poor outcome in patients with various urinary carcinomas.

Expression of CD147 is Associated with Prostate Cancer Progression

CD147 Expression Indicates Unfavourable Prognosis in Prostate Cancer

[Expression and Significance of CD147 Protein in Prostate Cancer].

Specific expression of CD147 in prostate cancer tissues

CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer.

Expression of CD147 As a Significantly Unfavorable Prognostic Factor in Hepatocellular Carcinoma

Expression and clinical significance of CD147 in genitourinary carcinomas.

Expression of CD147 in Advanced Non-Small Cell Lung Cancer Correlated with Cisplatin-Based Chemotherapy Resistance.

Large-Scale Single-Cell and Bulk Sequencing Analyses Reveal the Prognostic Value and Immune Aspects of CD147 in Pan-Cancer

Over-expressed CD 147 may be a reminder of tumor progression in cervical lesions : an immunohistochemical investigation with 494 cases

EMMPRIN/CD147 expression is associated with disease-free survival of patients with colorectal cancer

Expression and Clinical Significance of CD147 in Renal Cell Carcinoma: a Meta-Analysis.

CD147 and VEGF expression in advanced renal cell carcinoma and their prognostic value.

Expression of CD147 and Matrix Metalloproteinase-11 in Colorectal Cancer and Their Relationship to Clinicopathological Features.

Prognostic Role Of Extracellular Matrix Metalloproteinase Inducer/Cd147 In Gastrointestinal Cancer: A Meta-Analysis Of Related Studies

Prognostic significance of CD147 in patients with glioblastoma

The expression and clinical significance of CD147 in testicular tumor

[Highly Expressed CD147 on CD4⁺ Tumor Infiltrating Lymphocytes Promotes the Progress of Breast Cancer].

CD147 Expression in Pituitary Adenomas and Its Significance for Clinical Outcome

[Expression and Clinical Significance of HAb18G/CD147 in Malignant Tumors].

The expression of CD147 and PTEN in non small cell lung cancer and their correlation with clinical pathological factors